key: cord-0969237-h2p5gb2g authors: Bindu, Samik; Mazumder, Somnath; Bandyopadhyay, Uday title: Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: a current perspective date: 2020-07-10 journal: Biochem Pharmacol DOI: 10.1016/j.bcp.2020.114147 sha: b72eb594eb36efbd75993db2fd32832e528a38e8 doc_id: 969237 cord_uid: h2p5gb2g Owing to the efficacy in reducing pain and inflammation non-steroidal anti-inflammatory drugs (NSAIDs) are amongst the most popularly used medicines, confirming their position in the WHO’s Model List of Essential Medicines. With escalating musculoskeletal complications, as evident from 2016 Global Burden of Disease data, NSAID usage is evidently unavoidable. Apart from analgesic, anti-inflammatory and antipyretic efficacies, NSAIDs are further documented to offer protection against diverse critical disorders including cancer and heart attacks. However, data from multiple placebo-controlled trials and meta-analyses studies alarmingly signify the adverse effects of NSAIDs in gastrointestinal, cardiovascular, hepatic, renal, cerebral and pulmonary complications. Although extensive research has elucidated the mechanisms underlying the clinical hazards of NSAIDs, no review has extensively collated the outcomes on various multiorgan toxicities of these drugs together. In this regard, the present review provides a comprehensive insight of the existing knowledge and recent developments on NSAID-induced organ damage. It precisely encompasses the current understanding of structure, classification and mode of action of NSAIDs while reiterating on the emerging instances of NSAID drug repurposing along with pharmacophore modification aimed at safer usage of NSAIDs where toxic effects are tamed without compromising the clinical benefits. The review does not intend to vilify these ‘wonder drugs’; rather provide a careful understanding of their side-effects which would be beneficial in evaluating the risk-benefit threshold while rationally using NSAIDs at safer dose and duration. In this regard, the present review provides a comprehensive insight of the existing knowledge and 41 recent developments on NSAID-induced organ damage. It precisely encompasses the current Since the isolation of salicyclate from willow bark in around 1830s, followed by the discovery of 99 aspirin (acetyl salicyclate) by Felix Hoffman of Bayer industry, Germany in 1897, non steroidal anti-100 inflammatory drugs (NSAIDs) have been enjoying a blockbuster status in the pharmaceutical industry 101 [1] . In around 500 B.C., even before conceptualization of clinical trials and scientific knowledge, Hippocrates, wrote about the potential of willow bark and leaves in curing pain and fever. Generations oxidative stress and apoptosis has also strengthened its foothold as an independent pathway of 151 NSAID-induced cytopathology [24] . Other than gastrointestinal and cardiovascular complications, 152 habitual use of NSAIDs are also associated with nephrotoxicity and eventual renal failure [25] 153 together with other transient effects on water and electrolyte balance. In addition, idiosyncratic drug 154 toxicity by NSAIDs has also been significantly attributed to multiple incidences of hepatotoxicity [26] . 155 However, the exact mechanism involved in inflicting these adverse effects by NSAIDs is still elusive. All these data together eventually challenge the long-standing reputation of these 'wonder drugs' in 157 relation to their rampant medicinal use. Since, in the current context, NSAID use has become almost 158 unavoidable, a relatively safe usage of these drugs is the need of time which can avert the risk of organ 159 failure. To this end, precise understanding of the molecular mechanism and signalling pathways 160 involved in NSAID therapy is quintessential. In addition, chemical modification of FDA approved 161 NSAIDs, by pharmacophore modification, aimed at reducing their toxic effects and improving their 162 bioavailability without compromising the therapeutic effects is strongly advocated. Extensive studies 163 have been already undertaken to analyse the effects of NSAIDs at the molecular level besides 164 designing new combinatorial formulations in the form of NSAID-prodrugs with enhanced efficacy. Although there are discrete individual reports of organ-specific impact of these drugs where both 166 PGHS/PG-dependent as well as independent effects of NSAIDs have been implicated in their 167 cytotoxic actions, till date no comprehensive document is available which encompasses and accounts 168 the outcome of different randomized trials, meta-analyses, systemic reviews along with the mode of 169 action of NSAIDs and its effects on multiple organs in a coherent manner. In this article, we have tried 170 to provide an overall idea about the structure and function of NSAIDs with special emphasis on organ 171 damage as well as indicated the possible strategies of using these drugs in a safer approach by 172 discussing the previous contributions concurrent with recent understanding of the field. [189, 191, [194] [195] . Notably, PGHS-2 specific NSAIDs are less frequent in causing hepatotoxicity 936 compared to non-selective NSAIDs [194] . It is important to realize that NSAIDs can actually lead to 937 two major clinical patterns of hepatotoxicity; first being acute hepatitis (characterized by jaundice, [196] . In case of naproxen, ferrous iron (Fe 2+ )release 957 is responsible for naproxen-induced lipid peroxidation in rat liver microsomes [197] . Diclofenac was 958 found to be more toxic in drug metabolizing cells (isolated primary hepatocytes) compared to non-959 metabolizing cells (HepG2, FaO) . The toxicity may be due to diclofenac-induced mitochondrial 960 impairment along with a pointless and superfluous consumption of NADPH during the reduction of 961 N,5-hydroxydiclofenac to 5-hydroxydiclofenac; which is otherwise only oxidized to N,5-962 hydroxydiclofenac [197] . Mitochondrial permeability transition followed by production of reactive 963 oxygen species (ROS), mitochondrial swelling, oxidation of NADP, proteins and thiols are also linked 964 to diclofenac-induced liver injury [198] . Similar to diclofenac, oxidative stress is also connected with 965 salicylic acid-induced hepatotoxicity [199] . Notably, genetic predisposition has been an important 966 factor in diclofenac-induced idiosyncratic hepatotoxicity [ So shifting to PGHS-2 from PGHS-1 could be a better strategy; however PGHS-2 is 1042 not available without prescriptions [210]. Other than its role in AERD, NSAIDs are known to be 1043 frequently used in Community Acquired Pneumonia (CAP) or acute respiratory tract infections although NSAIDs have never been found to significantly reduce total symptoms or duration of 1045 acute respiratory infections. A nationwide case cross-over study showed that NSAID use during acute 1046 respiratory infection was associated with increased risk of MI [213]. In relation to CAP, different 1047 surveys and observational studies have also shown that half of the patients of CAP were treated with 1048 However, this extensive use of NSAIDs was neither approved by medical guidelines 1049 or any clinical data in pneumonia patients. From the mechanistic point of view NSAIDs rather worsen 1050 the situation by preventing the recruitment and functioning of polymorphonuclear neutrophils Ibuprofen was found to inhibit TNF-α and NF-κB transcriptional activity, thereby limiting pro-1052 inflammatory cytokine production Therefore, it may be presumed that NSAIDs could enhance 1053 pulmonary susceptibility to secondary infection to CAP. However, conflicting results were also 1054 obtained when role of NSAIDs were evaluated in animal models of pulmonary bacterial infection 1055 pre-existing medication and conditions should be considered before prescribing a drug. In 1056 one study, in human airway epithelial cells Parainfluenza virus (PIV3) reduced PGE2 generation However, celecoxib treatment on PIV3-infected airway epithelial cells significantly aggravated the 1058 PGE2 reduction along with reduced PGHS-2 expression [215]. In the current perspective of COVID-1059 19 outbreak, several speculations are popping up regarding the use of NSAIDs. Although 1060 indomethacin has been shown previously to block coronavirus RNA synthesis in dogs The first 3500years of aspirin history from its 1208 roots -A concise summary Endoplasmic reticulum stress response is involved in 1211 nonsteroidal anti-inflammatory drug-induced apoptosis NSAIDs in the Treatment of Postoperative Pain Use of mefenamic acid in the treatment of primary dysmenorrhea Shraddha Prakash Nonsteroidal Anti-Inflammatory Drugs Disease-Modifying Antirheumatic Drugs, Nonopioid Analgesics, & Drugs Used in Gout GOODMAN & GILMAN'S THE 1223 PHARMACOLOGICAL BASIS OF THERAPEUTICS An evidence-based update on nonsteroidal 1226 anti-inflammatory drugs Opioids versus nonsteroidal anti-1228 inflammatory drugs in noncancer pain Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect 1233 against Alzheimer's disease in rodent models NSAID Use and Incident Cognitive Impairment in a 1236 Population-based Cohort 1238 Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based 1239 cohort Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory 1242 agent Indomethacin has a potent antiviral activity 1245 against SARS coronavirus The multisystem adverse effects of NSAID therapy Monte Carlo simulations of laser-generated sea surface aureole Non-steroidal anti-1253 inflammatory drugs and risk of heart failure in four European countries: nested case-control 1254 study Combined use of nonsteroidal anti-1256 inflammatory drugs with diuretics and/or renin-angiotensin system inhibitors in the 1257 community increases the risk of acute kidney injury Current approaches to prevent NSAID-induced 1259 gastropathy--COX selectivity and beyond 1261 Mechanisms of Damage to the Gastrointestinal Tract From Nonsteroidal Anti-Inflammatory 1262 Emerging roles for cyclooxygenase-2 in gastrointestinal 1264 mucosal defense The effects of aspirin on gastric mucosal integrity, surface hydrophobicity, and prostaglandin 1267 metabolism in cyclooxygenase knockout mice Comparison of upper 1271 gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. 1272 VIGOR Study Group Renal toxicity of the nonsteroidal anti-inflammatory drugs Diclofenac-induced liver injury: a paradigm of idiosyncratic drug 1279 toxicity Seven steps to the diagnosis of NSAIDs 1281 hypersensitivity: how to apply a new classification in real practice? Non-steroidal Anti-inflammatory Drugs Chemical Analysis of Non-antimicrobial Veterinary Drug Residues in Food Nonsteroid 1287 drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with 1288 human gastrointestinal toxicity: a full in vitro analysis Nonsteroidal anti-1291 inflammatory drugs and cardiovascular safety -translating pharmacological data into clinical 1292 readouts Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): 1294 cyclooxygenase (COX) inhibition and beyond A turbulent decade for NSAIDs: update on current concepts of 1298 classification, epidemiology, comparative efficacy, and toxicity Pharmacodynamics and 1301 pharmacokinetics of nonsteroidal anti-inflammatory drugs in species of veterinary interest Pharmacogenetics of nonsteroidal anti-1304 inflammatory drugs Use of NSAIDs in treating patients with arthritis PharmGKB summary: ibuprofen pathways Genetic 1311 susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and 1312 ABCC2 genotypes ABCC2/Abcc2: a multispecific transporter with dominant excretory functions Structure and function of the MRP2 1317 (ABCC2) protein and its role in drug disposition Recent Advances in Hepatotoxicity of Non Steroidal Anti-1320 Inflammatory Drugs Glucuronidation of nonsteroidal anti-1322 inflammatory drugs: identifying the enzymes responsible in human liver microsomes, Drug 1323 Metab Dispos Disease-Modifying Effects of Long-Term and Continuous Use of 1325 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in Spondyloarthritis Safety of Oral Non-Selective Non-Steroidal Anti-1329 Inflammatory Drugs in Osteoarthritis: What Does the Literature Say? Nonsteroidal anti-inflammatory 1332 drugs for dysmenorrhoea Analgesic and anti-inflammatory drugs in sports: 1334 Implications for exercise performance and training adaptations Diclofenac attenuates 1338 inflammation through TLR4 pathway and improves exercise performance after exhaustive 1339 swimming Use of NSAIDs in triathletes: prevalence, level of awareness and reasons for use Widespread Use of Prescription 1344 Nonsteroidal Anti-Inflammatory Drugs Among U.S. Army Active Duty Soldiers Repurposing Drugs 1347 in Oncology (ReDO)-diclofenac as an anti-cancer agent Advances in antitumor effects of NSAIDs Nonsteroidal anti-inflammatory drugs as anticancer 1352 agents: mechanistic, pharmacologic, and clinical issues Nonsteroidal anti-inflammatory 1355 drugs in colorectal cancer: from prevention to therapy Anti-inflammatory Drugs for Cancer Prevention and Treatment: Emerging 1357 Options Potency of non-steroidal anti-inflammatory 1359 drugs in chemotherapy Mechanistic Role of MicroRNA in Cancer 1361 Chemoprevention by Nonsteroidal Anti-inflammatory Drugs Early and late effects of aspirin and naproxen on microRNAs in the lung and 1366 blood of mice, either unexposed or exposed to cigarette smoke Modeling of non-steroidal anti-inflammatory drug effect within 1369 signaling pathways and miRNA-regulation pathways Repurposing of approved cardiovascular 1371 drugs 1373 degli Uberti, Cyclooxygenase-2 inhibitors prevent the development of chemoresistance 1374 phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression Celecoxib targets breast cancer stem cells by inhibiting the synthesis of prostaglandin 1378 E2 and down-regulating the Wnt pathway activity ADD-1383 ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the 1384 effects of aspirin on disease recurrence and survival after primary therapy in common non-1385 metastatic solid tumours Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin 1391 randomised trial Long-term use of low-dose aspirin 1393 for cancer prevention: A 10-year population cohort study in Hong Kong Nonsteroidal 1396 anti-inflammatory drugs and pain in cancer patients: a systematic review and reappraisal of 1397 the evidence Non-steroidal anti-inflammatory drugs use is associated with reduced risk of inflammation-1400 associated cancers: NIH-AARP study Repurposing the Nonsteroidal Anti-inflammatory 1403 Drug Diflunisal as an Osteoprotective, Antivirulence Therapy for Staphylococcus aureus 1404 Phenotypic 1407 screening of nonsteroidal anti-inflammatory drugs identified mefenamic acid as a drug for the 1408 treatment of schistosomiasis Repurposing of Aspirin and Ibuprofen as 1410 Nonsteroidal anti-inflammatory drug sensitizes 1415 Mycobacterium tuberculosis to endogenous and exogenous antimicrobials Repurposing of FDA-Approved NSAIDs for DPP-4 Inhibition as an Alternative for Diabetes 1419 Mellitus Treatment: Computational and in Vitro Study Cyclooxygenase-2 (COX-2) inhibitors: 1421 future therapeutic strategies for epilepsy management Mefenamic acid shows neuroprotective effects and improves cognitive impairment in in 1425 vitro and in vivo Alzheimer's disease models A Comprehensive 1427 Review of Non-Steroidal Anti-Inflammatory Drug Use in The Elderly A randomized, double-blind, study of 1431 rofecoxib in patients with mild cognitive impairment Non-steroidal anti-inflammatory drugs and cognitive 1434 function: are prostaglandins at the heart of cognitive impairment in dementia and delirium? Effect of non-steroidal anti-inflammatory drugs on post-surgical 1438 complications against the backdrop of the opioid crisis Sedation and Pain Management in Burn 1440 Patients Misguided drug advice for COVID-19 Selective COX-2 Inhibitors: A Review of Their Structure-Activity 1444 Relationships Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like 1446 drugs Cyclooxygenase-3 (COX-3): filling in the gaps toward a 1448 COX continuum? The fight against rheumatism: from willow bark to COX-1 sparing drugs Cardiovascular Risk of Nonsteroidal Anti-1452 Inflammatory Drugs: An Under-Recognized Public Health Issue Identification of a phorbol ester-1454 repressible v-src-inducible gene Expression of a 1456 mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other 1460 analgesic/antipyretic drugs: cloning, structure, and expression Paracetamol: mechanism of action, applications and 1463 safety concern Introduction: mechanism of action of NSAIDs NSAIDs and Cardiovascular Diseases: Role of 1469 Reactive Oxygen Species Lipids: The Eicosanoids: Prostaglandins, Leukotrienes, and Thromboxanes, 1471 Integrative medical biochemistry : examination and board review Prostanoids in health and 1474 disease A 1476 single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses 1477 the selectivity of COX-2 specific inhibitors Cyclooxygenases: structural and functional insights MS/MS confirms that COX-1 drives vascular prostacyclin whilst gene expression pattern 1483 reveals non-vascular sites of COX-2 expression Eicosanoids, prostacyclin and cyclooxygenase in the 1485 cardiovascular system Non-steroid anti-inflammatory drugs, prostaglandins, and 1487 cancer Prostanoid receptors: 1489 subtypes and signaling The immunobiology of prostanoid receptor signaling in connecting innate 1491 and adaptive immunity Inhibition of 1493 mitochondrial complex I by various non-steroidal anti-inflammatory drugs and its protection 1494 by quercetin via a coenzyme Q-like action How mitochondria produce reactive oxygen species Selective scavenging of intra-mitochondrial 1499 superoxide corrects diclofenac-induced mitochondrial dysfunction and gastric injury: A novel 1500 gastroprotective mechanism independent of gastric acid suppression Indomethacin impairs mitochondrial dynamics by activating the PKCzeta-p38-DRP1 pathway 1505 and inducing apoptosis in gastric cancer and normal mucosal cells Nonsteroidal anti-1508 inflammatory drugs induce apoptosis in cutaneous T-cell lymphoma cells and enhance their 1509 sensitivity for TNF-related apoptosis-inducing ligand The proapoptotic effect of traditional and novel nonsteroidal 1512 anti-inflammatory drugs in mammalian and yeast cells Anti-Inflammatory Agents for Cancer Therapy Celecoxib decreases 1517 growth and angiogenesis and promotes apoptosis in a tumor cell line resistant to 1518 chemotherapy The prevalence of endoscopic gastric mucosal damage in patients 1521 with rheumatoid arthritis Frequency of NSAID 1523 induced peptic ulcer disease Cross-Sectional Study for Prevalence of Non-Steroidal Anti-Inflammatory Drug-1526 Induced Gastrointestinal, Cardiac and Renal Complications in India: Interim Report Guidelines for the appropriate use 1529 of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton 1530 pump inhibitors in patients requiring chronic anti-inflammatory therapy Quantifying the impact of NSAID-associated adverse events Current 1535 perspectives in NSAID-induced gastropathy Cyclooxygenase-2 biology Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory 1542 drugs: meta-analyses of individual participant data from randomised trials Cardiovascular events associated with the long-term use of NSAIDs: a 1546 review of randomized controlled trials and observational studies FDA labeling of NSAIDs: Review of nonsteroidal anti-1549 inflammatory drugs in cardiovascular disease Mitochondrial 1552 damage: a possible mechanism of the "topical" phase of NSAID induced injury to the rat 1553 intestine 1555 4-diamino-6-hydroxy pyrimidine inhibits NSAIDs induced nitrosyl-complex EPR signals 1556 and ulcer in rat jejunum Indomethacin, a non-steroidal anti-inflammatory drug, develops gastropathy by inducing 1559 reactive oxygen species-mediated mitochondrial pathology and associated apoptosis in gastric 1560 mucosa: a novel role of mitochondrial aconitase oxidation Melatonin reduces indomethacin-induced gastric mucosal cell apoptosis by preventing 1564 mitochondrial oxidative stress and the activation of mitochondrial pathway of apoptosis Gallic acid prevents nonsteroidal anti-inflammatory drug-induced 1568 gastropathy in rat by blocking oxidative stress and apoptosis Indomethacin inactivates gastric peroxidase to induce reactive-oxygen-mediated gastric 1572 mucosal injury and curcumin protects it by preventing peroxidase inactivation and scavenging 1573 reactive oxygen 1575 A novel antioxidant and antiapoptotic role of omeprazole to block gastric ulcer through 1576 scavenging of hydroxyl radical Gastroprotective effect of 1579 Neem (Azadirachta indica) bark extract: possible involvement of H(+)-K(+)-ATPase 1580 inhibition and scavenging of hydroxyl radical Mechanism of antiulcer effect of Neem (Azadirachta indica) leaf extract: effect on 1583 H+-K+-ATPase, oxidative damage and apoptosis Gastroprotective and anti-ulcer effects of 1586 oxymatrine against several gastric ulcer models in rats: Possible roles of antioxidant, 1587 antiinflammatory, and prosurvival mechanisms The gastroprotective effect of N-1589 acetylcysteine and genistein in indomethacin-induced gastric injury in rats Evaluating the mucoprotective effect of polydeoxyribonucleotide against indomethacin-1593 induced gastropathy via the MAPK/NF-kappaB signaling pathway in rats Nonsteroidal anti-inflammatory drug 1597 induces proinflammatory damage in gastric mucosa through NF-kappaB activation and 1598 neutrophil infiltration: anti-inflammatory role of heme oxygenase-1 against nonsteroidal anti-1599 inflammatory drug A randomised, placebo controlled, comparative trial of the 1602 gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis Nonsteroidal anti-1605 inflammatory drugs inhibit re-epithelialization of wounded gastric monolayers by interfering 1606 with actin, Src, FAK, and tensin signaling Gastric acid inhibitor aggravates 1610 indomethacin-induced small intestinal injury via reducing Lactobacillus johnsonii Nonsteroidal anti-inflammatory drugs and upper 1613 and lower gastrointestinal mucosal damage Non-steroidal anti-inflammatory 1615 drug-induced enteropathy A quantitative 1617 analysis of NSAID-induced small bowel pathology by capsule enteroscopy Visible small-intestinal 1620 mucosal injury in chronic NSAID users Current knowledge on non-steroidal anti-1622 inflammatory drug-induced small-bowel damage: a comprehensive review High mobility group box 1 promotes 1626 small intestinal damage induced by nonsteroidal anti-inflammatory drugs through Toll-like 1627 receptor 4 Role of bile in 1629 pathogenesis of indomethacin-induced enteropathy Role of dietary fibres, 1631 intestinal hypermotility and leukotrienes in the pathogenesis of NSAID-induced small 1632 intestinal ulcers in cats Involvement of gliadin, a component of wheat gluten, 1636 in increased intestinal permeability leading to non-steroidal anti-inflammatory drug-induced 1637 small-intestinal damage Lower gastrointestinal events in a double-blind trial of the cyclo-oxygenase-2 selective 1640 inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac The non-invasive exfoliated transcriptome (exfoliome) reflects the tissue-level transcriptome in a mouse model of NSAID 1645 enteropathy Lactobacillus casei treatment on small bowel injury in chronic low-dose aspirin users: a pilot 1649 randomized controlled study Yogurt 1652 Containing Lactobacillus gasseri Mitigates Aspirin-Induced Small Bowel Injuries: A 1653 Prospective, Randomized, Double-Blind Bifidobacteriumbreve Bif195 Protects Against 1658 Small-Intestinal Damage Caused by Acetylsalicylic Acid in Healthy Volunteers Emotion recollected in tranquility: lessons learned 1671 from the COX-2 saga Biological basis for the cardiovascular 1673 consequences of COX-2 inhibition: therapeutic challenges and opportunities Cardiovascular Safety of 1678 or Ibuprofen for Arthritis Imprecision: Limitations to Interpretation of a Large Randomized 1680 Clinical Trial Role of dose potency in the 1682 prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory 1683 drugs in the general population Coronary Risks Associated with Diclofenac and Other NSAIDs: An Update NSAIDs and cardiovascular risk The discovery of aspirin's antithrombotic effects, Tex Heart Inst 1691 Cyclooxygenase-1 and -2-1693 dependent prostacyclin formation in patients with atherosclerosis Aspirin and intracerebral hemorrhage: Where are we now? Oxidative Stress in Chronic Kidney Disease-Potential Therapeutic Role of Minerals, 1699 Vitamins and Plant-Derived Metabolites Risk of stroke associated with nonsteroidal anti-inflammatory drugs: a nested case-1702 control study Aspirin for primary prevention of cardiovascular 1705 disease: a meta-analysis with a particular focus on subgroups Cardiovascular complications of non-steroidal anti-inflammatory drugs Reply to letter regarding article, "evidence that links loss of 1713 cyclooxygenase-2 with increased asymmetric dimethylarginine: novel explanation of 1714 cardiovascular side effects associated with anti-inflammatory drugs Cyclooxygenase-2, Asymmetric Dimethylarginine, and the Cardiovascular 1719 Hazard From Nonsteroidal Anti-Inflammatory Drugs Vascular COX-2 modulates blood pressure and 1722 thrombosis in mice Diclofenac induces 1724 proteasome and mitochondrial dysfunction in murine cardiomyocytes and hearts Microarray analysis of NSAIDs-treated 1728 cardiomyocytes to search for genes involved in COX-2 inhibitor cardiotoxicity Pathophysiological aspects of nephropathy caused by non-steroidal anti-inflammatory 1732 drugs Effects of NSAIDs on kidney functions and cardiovascular 1734 system Non-steroidal Anti-inflammatory Drugs (NSAIDs) Systemic Use: The 1736 Risk of Renal Failure NSAIDs and kidney Nonsteroidal antiinflammatory drugs, cyclooxygenase-2, and 1740 the kidneys Significant Acute Kidney Injury Due to Non-1742 steroidal Anti-inflammatory Drugs: Inpatient Setting The Invisible Threat of Non-1745 steroidal Anti-inflammatory Drugs for Kidneys Effects of nonsteroidal 1747 anti-inflammatory meloxicam on stomach, kidney, and liver of rats Receptors and receptor mechanisms of endogenous 1751 platelet stimulatory and inhibitory mediators Concurrent use of diuretics, 1753 angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-1754 steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study Correction to: Cyclooxygenase-2 Selectively Controls Renal Blood Flow Through a 1757 Novel PPARbeta/delta-Dependent Vasodilator Pathway The Effects of cyclooxygenase-2 inhibitors and nonsteroidal 1760 anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, 1761 osteoarthritis, and type 2 diabetes mellitus Non-steroidal anti-1763 inflammatory drugs in chronic kidney disease: a systematic review of prescription practices 1764 and use in primary care Oxidant Mechanisms in Renal 1766 Injury and Disease Indomethacin-1768 induced renal damage: role of oxygen free radicals Vinpocetine 1771 reduces diclofenac-induced acute kidney injury through inhibition of oxidative stress, 1772 apoptosis, cytokine production, and NF-kappaB activation in mice Prospective Monitoring of Drug Use: Drug-Induced Liver Injury in a Primary Healthcare 1776 Center Non-steroidal anti-inflammatory drugs: What is the actual risk of liver 1779 damage? Drug-induced hepatotoxicity Hepatotoxicity of Nonsteroidal Anti-1782 Inflammatory Drugs: A Systematic Review of Randomized Controlled Trials Hepatocellular damage from non-steroidal anti-1785 inflammatory drugs Systematic review: ibuprofen-1787 induced liver injury Hepatotoxicity induced by coxibs: how 1790 concerned should we be? Nimesulide-induced hepatotoxicity: A systematic 1792 review and meta-analysis Possible mechanism of hepatocyte injury induced 1794 by diphenylamine and its structurally related nonsteroidal anti-inflammatory drugs Diclofenac toxicity to 1797 hepatocytes: a role for drug metabolism in cell toxicity Role of mitochondrial permeability transition in 1800 diclofenac-induced hepatocyte injury in rats Salicylic acid-induced hepatotoxicity triggered by oxidative stress Sulindac is excreted into bile by a canalicular bile salt pump and 1805 undergoes a cholehepatic circulation in rats Evaluation of naproxen-induced 1807 oxidative stress, hepatotoxicity and in-vivo genotoxicity in male Wistar rats Kupffer cell-derived 1810 cyclooxygenase-2 regulates hepatocyte Bcl-2 expression in choledocho-venous fistula rats Hemorrhagic stroke: intracerebral hemorrhage Risk of stroke associated with nonsteroidal anti-inflammatory 1815 drugs Risk of ischemic stroke and the use of individual non-steroidal anti-inflammatory drugs: A 1819 multi-country European database study within the SOS Project Nonaspirin nonsteroidal anti-1822 inflammatory drugs and hemorrhagic stroke risk: the Acute Brain Bleeding Analysis study Hemorrhagic Stroke in Patients Exposed to Nonsteroidal Anti-Inflammatory Drugs: A Meta-1826 Analysis of Observational Studies Cerebral microbleeds in 1828 patients with ischemic cerebrovascular disease taking aspirin or clopidogrel Aspirin Exacerbated Respiratory Disease: 1831 Epidemiology, Pathophysiology, and Management Aspirin-Exacerbated Respiratory Disease Role of group 2 innate lymphocytes in aspirin-exacerbated 1835 respiratory disease pathogenesis Risks 1837 Related to the Use of Non-Steroidal Anti-Inflammatory Drugs in Community-Acquired 1838 Pneumonia in Adult and Pediatric Patients Acute Respiratory 1840 Infection and Use of Nonsteroidal Anti-Inflammatory Drugs on Risk of Acute Myocardial 1841 Infarction: A Nationwide Case-Crossover Study Ibuprofen modulates NF-1843 kB activity but not IL-8 production in cystic fibrosis respiratory epithelial cells Parainfluenza virus infection enhances NSAIDs-induced 1847 inhibition of PGE2 generation and COX-2 expression in human airway epithelial cells Nucleocapsid protein of 1850 SARS-CoV activates the expression of cyclooxygenase-2 by binding directly to regulatory 1851 elements for nuclear factor-kappa B and CCAAT/enhancer binding protein COVID-19 and treatment with 1854 NSAIDs and corticosteroids: should we be limiting their use in the clinical setting? Venkata Basaveswara Rao Mandava, A 1857 perspective review on role of novel NSAID prodrugs in the management of acute 1858 inflammation A Practical Approach to Discontinuing NSAID 1860 Therapy Prior to a Procedure Prodrugs of nonsteroidal anti-inflammatory drugs (NSAIDs), more than 1864 meets the eye: a critical review Nonsteroidal 1866 antiinflammatory drugs and uncoupling of mitochondrial oxidative phosphorylation Synthesis and pharmacological evaluation of 1869 antiinflammatory mutual amide prodrugs Prodrugs of NSAIDs: A Review Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): 1873 Progress in Small Molecule Drug Development Hydrogen sulfide-based therapies: focus on H2S releasing 1876 NSAIDs Nitric oxide in the gastrointestinal tract: opportunities for drug 1878 development NSAIDs, coxibs, CINOD and H2S-releasing 1880 NSAIDs: what lies beyond the horizon Hydrogen 1882 Sulfide-Releasing Therapeutics: Translation to the Clinic A proof-of-concept, Phase 2 clinical trial of the gastrointestinal 1886 safety of a hydrogen sulfide-releasing anti-inflammatory drug Hydrogen sulfide prodrugs-a review The Role of Hydrogen Sulfide on 1891 Cardiovascular Homeostasis: An Overview with Update on Immunomodulation Hydrogen sulphide and the kidney: 1894 important roles in renal physiology and pathogenesis and treatment of kidney injury and 1895 disease The dangers of NSAIDs: look both ways Figure 1. Classification of non steroidal anti-inflammatory drugs (NSAIDs) based on structure PGHS-1/2 isoenzyme mediated prostanoid biosynthesis 1907 from arachidonic acid. Arachidonic acid is produced from phospholipids of the plasma membrane 1908 under the action of phospholipase A2. In addition to prostaglandin (PG) and thromboxane (Tx) 1909 formation by PGHS isoforms in a cell and tissue-specific manner, leukotrienes (LTEs) are other 1910 immune mediators which are produced by the enzyme 5-lipoxygenase (5-LO) Overview of NSAID-induced mitochondrial reactive oxidants production leading to 1914 cellular pathology. NSAID triggers electron leakage from complex I of the electron transport chain 1915 (ETC) leading to incomplete reduction of molecular oxygen followed by superoxide H2O2 may be scavenged by glutathione peroxidise (GPx) in 1919 presence of GSH. The oxidised glutathione (GSSG) is reduced back to GSH by glutathione reductase 1920 (GR) in presence of NADPH. Amplification of ROS will cause fall of mitochondrial membrane 1921 potential (∆Ψm) All these together contribute to a wide range of 1925 cellular pathologies. Dotted arrows indicate detrimental reactions involving free radicals The action of NSAIDs on major organs 1928 including stomach, small intestine, heart, liver, kidney, respiratory tract and brain is mainly mediated 1929 through PGHS-dependent prostanoid modulation and alteration of mitochondrial functional integrity 1930 leading to mitochondrial oxidative stress (MOS) generation, depolarization of mitochondrial 1931 transmembrane potential (ΔΨm) and consequently cell death. However, in heart low dose aspirin 1932 actually offers cardioprotection through anti-thrombotic effect Figure 6. Structural representation of typical NSAID prodrugs Samik Bindu: Conceptualization, Writing -Original Draft, Writing -Review & Editing Writing -Original Draft, Writing -Review & Editing, Figure Illustration Uday Bandyopadhyay: Conceptualization, Writing -Review & Editing, Supervision, Project 1944 administration, Funding acquisition Table 1. Categorization of NSAIDs based on PGHS-selective inhibitory action 1948 Categories PGHS isoform selectivity Representative NSAIDs Category 1 PGHS-1 and PGHS -2 Indomethacin, Aspirin, Diclofenac, Naproxen , Ibuprofen Category 2 5-50 fold selectivity for PGHS -2 Meloxicam including HS-sulindac, HS-ibuprofen and HS-aspirin have also been reported to act as anticancer 1150 agents. NBS-1120, which releases H2S, NO and aspirin, simultaneously, has been attributed with the 1151 most potent anti-cancer potency [230] . Since H2S has been linked to cardiovascular homeostasis and 1152 normal physiology of kidney, H2S prodrugs can be also effective against CVD and renal failure [231-